Search of: "Lanreotide" - List Results

Home


	List Results


	Refine Search


	Results by Topic


	Results on Map


	Search Details

Found 31 studies with search of:

"Lanreotide"

Hide studies that are not seeking new volunteers.

Display Options

1	Recruiting	GH, IGF-I and Somatostatin Analogues in Hepatocellular Carcinoma
		Condition:	Advanced Hepatocellular Carcinoma
		Interventions:	Drug: Octreotide-LAR, Lanreotide Autogel; Drug: Octreotide-LAR or Lanreotide Autogel; Other: Locoregional treatments

2	Completed	Lanreotide Autogel-120 mg as First-Line Treatment of Acromegaly
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide-Autogel 120 mg

3	Not yet recruiting	Prevention of Lymphorrhea by Lanreotide in Axillary Dissection for Breast Cancer
		Condition:	Lymphocele
		Interventions:	Drug: Lanreotide LP 90; Drug: Placebo lanreotide

4	Active, not recruiting	Assessment of the Ability of Subjects With Acromegaly or Their Partners to Administer Somatuline Autogel
		Condition:	Acromegaly
		Interventions:	Drug: Somatuline Autogel (lanreotide acetate); Behavioral: Home administration

5	Recruiting	Treatment of the Dumping Syndrome With Lanreotide Autogel®
		Condition:	Dumping Syndrome
		Intervention:	Drug: Somatuline (Lanreotide Autogel®)

6	Active, not recruiting	Lanreotide as Treatment of Polycystic Livers
		Conditions:	Polycystic Liver Disease; Hepatomegaly; Liver Diseases; Polycystic Kidney, Autosomal Dominant
		Interventions:	Drug: Placebo; Drug: Lanreotide

7	Withdrawn	Study to Evaluate Patients With Acromegaly Treated With Lanreotide Autogel (Somatuline ATG)
		Condition:	Acromegaly
		Intervention:	Drug: lanreotide (Autogel formulation)

8	Completed	Comparable Effects of Lanreotide Autogel and Octreotide LAR on GH, IGF-I Levels and Patient Satisfaction
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide Autogel and Octreotide LAR

9	Active, not recruiting	Lanreotide Autogel and Pegvisomant Combination Therapy in Acromegalic Patients
		Condition:	Acromegaly
		Interventions:	Drug: lanreotide (Autogel formulation); Drug: Pegvisomant

10	Completed	Efficacy and Safety Study of Varying Doses of Lanreotide Autogel in Patients With Acromegaly
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide (Autogel formulation)

11	Completed	Impact of Somatostatin Analogs vs. Surgery on Glucose Metabolism in Acromegaly
		Condition:	Acromegaly
		Interventions:	Drug: Octreotide-LAR or lanreotide; Procedure: Transsphenoidal adenomectomy

12	Completed	Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly
		Condition:	Acromegaly
		Intervention:	Drug: lanreotide (Autogel formulation), duration of treatment 24-56 weeks, depending on dose interval

13	Terminated	Lanreotide (Somatuline Autogel) in Thyroid-Associated Ophthalmopathy Treatment
		Condition:	Thyroid-Associated Ophthalmopathy
		Intervention:	Drug: Lanreotide (Autogel formulation). Duration of treatment - 3 injections, 1 every 28 days

14	Recruiting	Lanreotide as Primary Treatment for Acromegalic Patients With Pituitary Gland Macroadenoma
		Condition:	Acromegaly Associated With Pituitary Gland Macroadenoma
		Intervention:	Drug: Lanreotide autogel

15	Completed	Efficacy and Safety of Lanreotide Versus Placebo for Treatment of Patients With Digestive Fistulae
		Condition:	Digestive Fistulae
		Interventions:	Drug: Lanreotide microparticles; Drug: Placebo

16	Completed	Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide (Autogel formulation)

17	Recruiting	Efficacy and Safety of Lanreotide Microparticles as Palliative Treatment in Peritoneal Carcinomatosis
		Conditions:	Intestinal Obstruction; Carcinoma; Peritoneal Neoplasms
		Interventions:	Drug: Lanreotide (microparticle formulation); Other: Placebo

18	Completed	Efficacy and Safety of Lanreotide Autogel (60, 90 or 120 mg) in Acromegalic Patients
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide (Autogel formulation)

19	Recruiting	Study of Lanreotide Autogel in Non-Functioning Entero-Pancreatic Endocrine Tumours
		Condition:	Endocrine Tumors
		Interventions:	Drug: lanreotide (Autogel formulation); Other: Placebo

20	Recruiting	Efficacy and Safety of Lanreotide Autogel in Tumour Stabilization of Patients With Progressive Neuroendocrine Tumours
		Condition:	Neuroendocrine Tumours
		Intervention:	Drug: lanreotide (Autogel formulation)

21	Not yet recruiting	Open Label Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel 120 mg in Acromegalic Subjects Who Are Biochemically Controlled on Long Term Treatment With Octreotide LAR 10 or 20 mg
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide Autogel 120 mg

22	Terminated	Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome
		Condition:	Malignant Carcinoid Syndrome
		Interventions:	Drug: lanreotide Autogel (somatostatin analogue); Drug: Sandostatin long acting release (LAR) Depot (somatostatin analogue)

23	Completed	Efficacy and Tolerability of Lanreotide (Autogel 120 mg) in Patients With Acromegaly
		Condition:	Acromegaly
		Intervention:	Drug: lanreotide (Autogel formulation), duration of treatment 46-48 weeks

24	Recruiting	Somatuline Autogel Preference and Health Economy Study
		Condition:	Neuroendocrine Tumour With Carcinoid Symptoms
		Intervention:	Drug: Lanreotide Autogel

25	Completed	Somatuline Autogel: Acromegaly Self/Partner Injection Study
		Condition:	Acromegaly
		Intervention:	Drug: Lanreotide (Autogel formulation)

26	Recruiting	Somatuline® Depot (Lanreotide) for Acromegaly Post-Marketing Observational Study
		Condition:	Acromegaly
		Intervention:

27	Not yet recruiting	Use of Somatostatin Analogue Therapy as Primary Medical Treatment of Acromegaly
		Condition:	Acromegaly
		Intervention:	Drug: Somatuline Autogel

28	Completed	A Study to Evaluate the Risk of Developing a Heart Condition Called Valvular Regurgitation in Patients With Acromegaly Treated With Either Lanreotide or Octreotide
		Condition:	Acromegaly
		Intervention:

29	Completed	Cardiovascular Outcome After Surgery or Somatostatin Analogues
		Condition:	Acromegaly
		Intervention:

30	Not yet recruiting	Non Interventional Post Marketing Programme in Acromegaly
		Condition:	Acromegaly
		Intervention:

31	Not yet recruiting	Non Interventional Post Marketing Programme in Neuroendocrine Tumours
		Condition:	Neuroendocrine Tumors
		Intervention:

RSS Feed for studies found by your search that were received in the last 14 days

Download Options